Strata Critical Medical, Inc. (SRTA) — Fundamental Analysis

Snapshot & Big Picture

Strata Critical Medical, Inc. (ticker: SRTA) is a medical company that has been navigating a turbulent growth phase over the past several years. The business has scaled revenue significantly from its early fiscal years, but profitability has remained elusive, with persistent operating and EBITDA losses across nearly every annual period on record. The company changed its fiscal year-end from September 30 to December 31 at some point between 2021 and 2022, which creates a transition period stub in the data and makes direct year-over-year comparisons across that boundary somewhat approximate. With a debt-free balance sheet (debt-to-equity is null or zero across all periods where data is available) and consistently strong current ratios, the liquidity picture has historically been a relative bright spot even as the business burns cash at the operating level.

Latest Quarter Snapshot

The most recent quarterly filing covers the period ending March 31, 2026 — this is more current than the annual figures and offers the freshest read on the business. Key highlights from that quarter:

This quarter is notably significant: EBITDA came in at just $86,000 — barely above zero, but that represents a dramatic improvement from the deeply negative EBITDA figures that have characterized the company's recent annual results. The operating margin of -4.4% is the least negative on record, and a positive net margin of 3.2% is a meaningful data point. Whether this represents a structural inflection toward profitability or a one-quarter anomaly remains to be seen, but it is the most encouraging quarter in the company's filing history.

Profitability — Multi-Year Trend

Looking at profitability across annual filings, the picture is one of gradual but uneven improvement from a very deep hole. Operating margins have been negative throughout the entire filing history, though the magnitude of losses has been shrinking.

A few notable observations: The gross margin data only became available in the filings starting with fiscal year 2024, hovering around 20–21%, which is relatively thin for a medical company and underscores the cost-intensive nature of the business model. Operating losses have been shrinking meaningfully in the most recent two annual periods — from -30.3% in 2023 to -15.3% in 2024 and -11.3% in 2025. The positive net margin in FY2025 (+21.0%) is worth flagging but should be viewed carefully, as it diverges significantly from operating and EBITDA figures, suggesting it may be driven by non-operating items (e.g., gains, tax benefits, or other below-the-line items) rather than core business profitability. Revenue also declined sharply from FY2023's $225.2M to FY2024's $146.8M before recovering to $197.1M in FY2025, adding some lumpiness to the growth story.

Financial Health

SRTA's balance sheet liquidity has consistently been a strength. The current ratio — a measure of short-term assets relative to short-term liabilities — has remained well above 1.0x across all periods, and in many early periods was exceptionally high.

The high current ratios across the board suggest the company has maintained ample short-term liquidity — likely supported by cash raised through equity offerings, which is common for growth-stage medical businesses that are not yet cash flow positive. The absence of debt (or near-zero debt) is a positive, as it means there is no interest burden compounding the operating losses. The current ratio has been gradually normalizing downward from the very elevated levels seen in 2021, which is typical as a company scales up operations and deploys capital.

Growth

The pre-calculated revenue CAGRs below reflect the company's growth trajectory across available windows. Note that the fiscal year change (from September 30 to December 31) affects the five-year calculation, which anchors from the September 2021 fiscal year-end.

The five-year CAGR of 31.3% reflects a period of rapid scaling as the company grew from roughly $50M in revenue to nearly $200M. However, the more recent three-year CAGR of just 10.5% shows that growth has moderated considerably — partly due to the revenue dip in FY2024 — suggesting the hyper-growth phase has passed and the business is now in a more mature, slower-growth mode where margin improvement becomes the key value driver.

Plain English Summary

Strata Critical Medical (SRTA) is a medical company that has spent the better part of the last several years growing rapidly while losing money. The good news is that the losses are getting smaller: operating margins have improved from around -48% in fiscal 2021 to -11% in fiscal 2025, and the most recent quarter (ending March 2026) came in at near-breakeven EBITDA with a small positive net income — the closest the company has ever come to actual profitability. The balance sheet is clean with no apparent debt and a current ratio well above 1.0x, meaning there's no imminent solvency concern. Revenue growth has been real but lumpy, with a sharp decline in 2024 followed by a recovery in 2025, and the longer-term growth rate has cooled from above 30% annually to roughly 10% over the most recent three years. Gross margins around 20–21% are thin, and the company will need to either expand them or significantly cut operating costs to reach sustainable profitability. Altogether, SRTA looks like a company that may be approaching a profitability inflection point, but investors should watch closely to see whether Q1 2026's near-breakeven result is a repeatable trend or a one-quarter bright spot.

Source Filings

• 10-Q filed May 6, 2026 — Period ending March 31, 2026
• 10-K filed March 3, 2026 — Fiscal year ending December 31, 2025